UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape
UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.
Contents8 sections
UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape
UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development. With Phase 3 superiority data, a September 2024 FDA approval, and early awareness outpacing established rivals, Bimzelx is reshaping the IL-17 inhibitor class and forcing a strategic reckoning for incumbents and pipeline players alike.
Key Takeaways
- Bimzelx achieved reduced disease activity in 49% of psoriatic arthritis patients versus 38% for Skyrizi in a 553-patient Phase 3 head-to-head trial, establishing clear efficacy superiority at 16 weeks.
- The FDA approved Bimzelx for active psoriatic arthritis in September 2024, expanding beyond its existing plaque psoriasis authorization and giving UCB a new growth pillar in immunology.
- Early survey data from Spherix Global Insights indicates Bimzelx awareness is tracking ahead of both Skyrizi and Rinvoq just three months into its PsA launch — a rare feat against AbbVie's entrenched immunology franchise.
- For BD and regulatory teams, the results sharpen the case for IL-17A/IL-17F dual inhibition as a competitive differentiator and raise the bar for future head-to-head trial design in PsA.
Bimzelx Achieves Superior Efficacy in Psoriatic Arthritis Trial
UCB's Phase 3 head-to-head study enrolled 553 adults with active psoriatic arthritis and randomized them to either Bimzelx (bimekizumab) or AbbVie's Skyrizi (risankizumab). At 16 weeks, 49% of patients on Bimzelx achieved reduced disease activity compared with 38% of those on Skyrizi — an 11-percentage-point gap that UCB characterized as statistically significant and clinically meaningful. The trial measured joint relief as a primary endpoint, and Bimzelx's IL-17A/IL-17F dual inhibition mechanism appeared to drive the advantage over Skyrizi's IL-23 blockade pathway.
UCB reported that Bimzelx was generally well tolerated in the study, with no new safety signals observed. The safety profile was consistent with prior data from the drug's plaque psoriasis program, where oral candidiasis and injection-site reactions were the most commonly reported adverse events. The 553-patient cohort provided sufficient statistical power to support the superiority claim, and UCB has indicated it plans to submit the full dataset for peer-reviewed publication.
The FDA approved Bimzelx for active psoriatic arthritis in September 2024, building on the authorization UCB secured in plaque psoriasis. The PsA indication represents a substantial commercial opportunity: the global psoriatic arthritis market is projected to exceed $15 billion by 2030, and capturing even mid-single-digit share from entrenched TNF and IL-23 inhibitors would translate into meaningful revenue for UCB. The approval also gives prescribers a new mechanism-of-action option in a class where head-to-head superiority data has been scarce. FDA drug approvals database
How Does Bimzelx's Mechanism Compare to IL-23 Inhibition in PsA?
Bimzelx blocks both IL-17A and IL-17F, two cytokines involved in the inflammatory cascade that drives joint damage and skin manifestations in psoriatic arthritis. Skyrizi, by contrast, inhibits IL-23, an upstream regulator that sits higher in the inflammatory pathway. The head-to-head data suggests that direct IL-17A/IL-17F dual blockade may offer stronger short-term joint outcomes than IL-23 inhibition, though long-term data on radiographic progression and durability of response is still needed.
The competitive implications extend beyond the UCB-AbbVie rivalry. AbbVie's Rinvoq (upadacitinib), a JAK inhibitor, also holds a PsA indication and has been gaining share on the strength of its oral administration and broad label. Yet Spherix Global Insights survey data from February 2025 found that Bimzelx awareness among rheumatologists was tracking ahead of both Rinvoq and Skyrizi just three months into its PsA launch — a striking result given AbbVie's dominant commercial infrastructure and established relationships with prescribers. Awareness does not automatically convert to prescriptions, but the early trajectory suggests UCB's clinical messaging around head-to-head superiority is cutting through. EMA product page for Bimzelx
For market watchers, the critical question is whether UCB can sustain this momentum as payers weigh formulary access and as longer-term safety data accumulates. IL-17 inhibitors carry known risks around fungal infections and inflammatory bowel disease flares, and post-market surveillance will be closely scrutinized by regulators and health technology assessment bodies.
Implications for Pharmaceutical Business Development and Regulatory Strategy
The Bimzelx-Skyrizi head-to-head data creates immediate ripple effects across the immunology BD landscape. For companies evaluating acquisition or licensing targets in the IL-17 space, UCB's results validate the mechanism as commercially competitive against IL-23 blockers and may lift valuations for early-stage IL-17A/IL-17F programs. Conversely, the data puts pressure on companies with IL-23-dominant pipelines to either generate their own head-to-head superiority data or differentiate on safety, convenience, or pricing.
From a regulatory strategy standpoint, UCB's success in securing a PsA label on the strength of a head-to-head trial sets a precedent that other sponsors may seek to replicate. Regulatory teams at competing firms should anticipate that the FDA and EMA will increasingly expect active-comparator data — not just placebo-controlled results — for new PsA entrants, particularly when pursuing superiority or differentiated labeling claims. Post-market surveillance requirements for IL-17 inhibitors will also demand rigorous pharmacovigilance infrastructure, and companies entering this space should budget accordingly.
For AbbVie, the Skyrizi result is a strategic inflection point. The drug remains a multi-billion-dollar franchise with strong positions in Crohn's disease, psoriasis, and PsA, and AbbVie is unlikely to cede the immunology throne without a response. Expect the company to lean into Skyrizi's established safety database, its subcutaneous dosing convenience, and its broader label to defend market share. Rinvoq's oral formulation offers another angle of defense, though JAK inhibitor class-wide safety warnings from the FDA continue to constrain its positioning.
UCB's investor relations materials suggest the company views Bimzelx as a potential blockbuster across multiple IL-17-driven indications, including ankylosing spondylitis and hidradenitis suppurativa, where it also holds approvals or late-stage programs. If the PsA launch continues to outpace early expectations, UCB may accelerate investment in lifecycle management and combination studies. ClinicalTrials.gov — Bimekizumab PsA studies
Frequently Asked Questions
What is the primary mechanism of action for Bimzelx and Skyrizi?
Bimzelx (bimekizumab) is a humanized monoclonal antibody that inhibits both interleukin-17A and interleukin-17F, two pro-inflammatory cytokines central to the pathogenesis of psoriatic arthritis and plaque psoriasis. Skyrizi (risankizumab) targets interleukin-23, an upstream cytokine that regulates the differentiation and survival of T-helper 17 cells, which in turn produce IL-17. The distinction matters because direct IL-17A/IL-17F blockade may achieve more immediate suppression of joint inflammation, while IL-23 inhibition modulates a broader immune pathway with a potentially different efficacy and safety profile.
What are the key safety considerations for IL-17 inhibitors in psoriatic arthritis?
Across the IL-17 class, oral candidiasis is the most frequently reported adverse event, occurring in a notable minority of patients. Inflammatory bowel disease flares — including new-onset or worsening Crohn's disease and ulcerative colitis — have also been observed, prompting regulatory scrutiny and labeling precautions. In the Bimzelx PsA head-to-head trial, UCB reported no new safety signals, and the overall tolerability profile was consistent with prior plaque psoriasis studies. Long-term post-market data will be essential to fully characterize the risk-benefit balance, particularly in patients with comorbid gastrointestinal conditions.
How might these trial results affect future market share projections for these drugs?
The 49% versus 38% efficacy gap, combined with early awareness data showing Bimzelx outpacing both Skyrizi and Rinvoq in the first quarter post-launch, suggests UCB is positioned to capture meaningful PsA market share — potentially in the high single to low double digits within two to three years, depending on formulary access and payer negotiations. Skyrizi's established base in psoriasis and Crohn's disease provides a buffer, and Rinvoq's oral dosing remains a competitive differentiator. Analysts should watch prescription trend data from IQVIA and Symphony Health through mid-2025 for early signals of whether awareness is converting to sustained uptake. The head-to-head data also raises the competitive bar: future PsA entrants will face pressure to generate active-comparator data at launch, which could slow the pace of new approvals but raise the quality of evidence available to prescribers.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Follow Bimzelx developments
EMA psoriatic arthritis alerts and Bimzelx pipeline updates, every Monday.
This article follows our editorial standards. Report a correction via editorial contact.
